ResMed

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ResMed and other ETFs, options, and stocks.

About RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases.

CEO

Michael J. Farrell

CEOMichael J. Farrell

Employees

10,600

Employees10,600

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1989

Founded1989

Employees

10,600

Employees10,600

RMD Key Statistics

Market cap

28.79B

Market cap28.79B

Price-Earnings ratio

18.61

Price-Earnings ratio18.61

Dividend yield

1.24%

Dividend yield1.24%

Average volume

1.76M

Average volume1.76M

High today

$199.56

High today$199.56

Low today

$194.06

Low today$194.06

Open price

$194.54

Open price$194.54

Volume

1.20M

Volume1.20M

52 Week high

$293.81

52 Week high$293.81

52 Week low

$180.27

52 Week low$180.27

Stock Snapshot

As of today, ResMed(RMD) shares are valued at $198.57. The company's market cap stands at 28.79B, with a P/E ratio of 18.61 and a dividend yield of 1.24%.

During the trading session on 2026-07-15, ResMed(RMD) shares reached a daily high of $199.56 and a low of $194.06. At a current price of $198.57, the stock is +2.3% higher than the low and still -0.5% under the high.

Trading activity shows a volume of 1.2M, compared to an average daily volume of 1.76M.

Over the past 52 weeks, ResMed(RMD) stock has traded between a high of $293.81 and a low of $180.27.

RMD News

TipRanks 12h

ResMed price target lowered to $220 from $235 at Mizuho

Mizuho lowered the firm’s price target on ResMed (RMD) to $220 from $235 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical...

TipRanks 2d

Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged

Morgan Stanley analyst David Bailey maintained a Hold rating on Resmed yesterday and set a price target of $230.00. TipRanks has entered a new arena in the inv...

MarketWatch 2d

ResMed Inc. stock falls Monday, underperforms market - MarketWatch

...

Analyst ratings

67%

of 30 ratings

Buy

66.7%

Hold

26.7%

Sell

6.7%

More RMD News

Simply Wall St 5d

How Investors Are Reacting To ResMed Selling MatrixCare To Refocus On Core Sleep Health

ResMed has already agreed to sell its underperforming MatrixCare aged care software unit to private equity firm Frazier Healthcare Partners for about US$490 mil...

TipRanks 6d

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Simply Wall St 6d

ResMed After Russell Growth Index Exits Is The Undervalued Narrative Still Intact

Advertisement Index changes put ResMed in focus ResMed (RMD) has dropped from several Russell growth indices, including the Russell 1000 Growth and Russell 30...

Benzinga 6d

ResMed Analyst Backs Portfolio Reset

The move reflects ResMed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcar...

People also own

Based on the portfolios of people who own RMD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.